SEC Filings




Filing Date Form Description
September 13, 2022 6-K On September 13, 2022, Biophytis S.A. issued a press release announcing that the Paris Court of appeal rules in favour of Biophytis in the case against Negma Group Ltd. PDF
September 07, 2022 6-K On September 7, 2022, Biophytis S.A. issued a press release announcing very promising top line results of its phase 2-3 COVA clinical study in COVID-19 related to respiratory failure. PDF
July 04, 2022 6-K On July 4, 2022, Biophytis S.A. issued a press release providing an update on the development of Sarconeos (BIO101) in Covid-19 at the 4th Annual Longevity Therapeutics Summit. PDF
June 30, 2022 6-K On June 30, 2022, Biophytis S.A. issued a press release announcing the drawing of the second tranche of ORNANE under the 2021 Atlas Contract for €4 million. PDF
June 27, 2022 6-K On June 27, 2022, Biophytis S.A. issued a press release presenting the development of Sarconeos (BIO101) in Phase 3 for the treatment of Sarcopenia at the 15th SCWD International Congress. PDF
June 22, 2022 6-K On June 22, 2022, Biophytis S.A. issued a press release announcing the results of the Combined General Meeting held on June 21, 2022. PDF
June 16, 2022 6-K On June 16, 2022, Biophytis S.A. issued a press release presenting preclinical efficacy data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), a rare neuromuscular disease. PDF
June 3, 2022 6-K On June 3, 2022, Biophytis S.A. issued a press release announcing the Convening of Another Combined General Meeting at a Later Date. PDF
May 12, 2022 6-K On May 12, 2022, Biophytis S.A. issued a press release announcing its participation at the Bio International Convention in San Diego from the 13th to the 16th of June PDF
April 21, 2022 20-F Annual Report Pursuant To Section 13 Or 15(D) Of The Securities Exchange Act Of 1934 For The Fiscal Year Ended December 31, 2021 PDF
April 19, 2022 6-K On April 19, 2022, Biophytis S.A. issued a press release announcing that the company will present Sarconeos (Bio101) Development Program in Sarcopenia at the 12th annual International Conference on Frailty and Sarcopenia Research (ICFSR) in Boston, April 20-22, 2022 PDF
April 7, 2022 6-K On April 7, 2022, Biophytis S.A. issued a press release announcing 2021 Operational and Financial Results and Gives Updates on 2022 Perspectives PDF
April 5, 2022 6-K On April 5, 2022, Biophytis S.A. issued a press release announcing the appointment of Philippe Rousseau as Chief Financial Officer PDF
March 16, 2022 6-K On March 16, 2022, Biophytis S.A. issued a press release announcing that the company will participate in a key conference on mobility for the elderly PDF
February 4, 2022 6-K On February 3, 2022, Biophytis S.A. issued a press release announcing that the company received approval from ANVISA (Brazil) to give access to Sarconeos (BIO101) to hospitalized COVID-19 patients through an Expanded Access Program PDF
December 23, 2021 6-K On December 22, 2021, Biophytis S.A. issued a press release announcing the drawing of the last tranche of ORNANE under the 2020 Atlas contract for 3 million. PDF
December 17, 2021 6-K On December 16, 2021, Biophytis S.A. issued a press release announcing that the company is to meet with FDA to advance Sarconeos (BIO101) development in Sarcopenia from Phase 2 to Phase 3 PDF
November 23, 2021 6-K On November 22, 2021, Biophytis S.A. issued a press release announcing the obtaining of a new 10M€ loan structure with Kreos Capital PDF
November 15, 2021 6-K On November 15, 2021, Biophytis S.A. issued a press release announcing US centers to restart recruitment for the COVA phase 2-3 study with Sarconeos (BIO101) in COVID 19 PDF
October 29, 2021 6-K On October 29, 2021, Biophytis S.A. issued a press release reporting Restated Financial Statements for Previous Periods and as of June 30, 2021. PDF
October 29, 2021 20-F Annual Report Pursuant To Section 13 Or 15(D) Of The Securities Exchange Act Of 1934
For The Fiscal Year Ended December 31, 2020
PDF
October 29, 2021 6-K On October 28, 2021, Biophytis S.A. (the “Company” issued its Interim Financial Report for the first half of fiscal year 2021. PDF
October 06, 2021 6-K Biophytis S.A. issued a press release announcing it will host a virtual key opinion leader (KOL) event on October 6th, 2021, on its lead projects, Sarconeos (BIO101) for the treatment of COVID-19 and Sarcopenia PDF
October 05, 2021 6-K On October 4, 2021, Biophytis S.A. issued a press release announcing the drawing of 2 new tranches of ORNANE under the 2020 Atlas contract for € 6 million PDF
October 04, 2021 6-K Biophytis announces promising full results from the SARA-INT Phase 2b trial of Sarconeos (BIO101) in Sarcopenia at the 11th annual International Conference on Frailty and Sarcopenia Research (ICFSR)
September 29 – October 2, 2021
PDF
September 30, 2021 6-K Biophytis to Present Full Results from the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29–October 2, 2021 PDF
September 17, 2021 6-K Biophytis reports H1 2021 financial results and provides business update PDF
September 15, 2021 6-K Biophytis announces DMC second interim analysis efficacy results in the promising zone allowing continuation of phase 2/3 COVA study with Sarconeos (BIO101) in COVID-19 PDF
June 30, 2021 6-K Biophytis announces that the results of SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be released by August 2021 PDF
June 30, 2021 6-K Biophytis announces that it will secure the manufacturing of Sarconeos (BIO101) for COVID-19 with a global CDMO and the next milestones for the COVA Phase 2-3 study PDF
June 18, 2021 6-K Biophytis announces new convertible bonds financing upt to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 million PDF
May 12, 2021 6-K Biophytis Completed the Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis PDF
May 11, 2021 6-K Results of the Combined General Meeting on May 10, 2021 PDF
April 30, 2021 6-K Biophytis Second Combined General Meeting to take place on May 10, 2021 without the physical presence of its shareholers PDF
April 29, 2021 6-K Biophytis Receives €980,000 DeepTech Funding from BPI France for the Development of Macuneos (BIO201) in Dry AMD PDF
April 27, 2021 6-K Convening of another Combined General Meeting at a later date PDF
April 26, 2021 6-K Biophytis gives operational perspectives on its Sarconeos (BIO101) ahead of its upcoming AGM on April 26, 2021 PDF
March 22, 2021 6-K Biophytis gives update on its Phase 2-3 COVA study on COVID-19 PDF
March 19, 2021 6-K Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis against Negma Group Ltd PDF
March 12, 2021 6-K Annual General Meeting will take place on April 26, 2021 PDF
March 11, 2021 20-F Annual Report for the Fiscal Year Ended Dec 31, 2020 PDF
Feb 26, 2021 6-K Biophytis Reports 2020 Full Year Results PDF
Feb 17, 2021 6-K Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial PDF
Feb 16, 2021 6-K Report of Foreign Private Issuer PDF
Feb 9, 2021
Final Prospectus PDF
Feb 9, 2021 F-1 Amendment No 3 PDF
Feb 8, 2021 FWP Free Writing Prospectus PDF
Feb 4, 2021 F-8A For Registration of Certain Classes of Securities Pursuant to Section 12(b) or (g) PDF
Feb 4, 2021 F-1 Amendment No 2 PDF
Feb 2, 2021 FWP Free Writing Prospectus PDF
Feb 2, 2021 F-1 Amendment No 1 PDF
Jan 19, 2021 F-1 Form F-1 PDF
Dec 23, 2020 F-1 Draft Registration Statement PDF
Nov 20, 2020 F-1 Draft Registration Statement PDF